GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CKD-386

Company
Chong Kun Dang Pharmaceutical
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT03609606

    A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

    Not yet reported Chong Kun Dang Pharmaceutical 69 participants Est. completion 2018-09-27 1 site
    Other conditions: Dyslipidemias, Hypertension
    View official trial listing →
  • Status unknown NCT NCT03920579

    A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

    Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2019-05 1 site Stand-alone
    Other conditions: Hypertension, Dyslipidemias
    View official trial listing →
  • Status unknown NCT NCT04223895

    A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers

    Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2020-06-15 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04312698

    Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

    Not yet reported Chong Kun Dang Pharmaceutical 100 participants Est. completion 2021-06-18 1 site
    Other conditions: Dyslipidemia Patients With Hypertension
    View official trial listing →
  • Completed NCT NCT04673864

    A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

    Not yet reported Chong Kun Dang Pharmaceutical 66 participants Est. completion 2021-03-30 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT04694989

    A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

    Not yet reported Chong Kun Dang Pharmaceutical 62 participants Est. completion 2021-05-04 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT04987970

    A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

    Not yet reported Chong Kun Dang Pharmaceutical 60 participants Est. completion 2021-11-27 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05245084

    A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

    Not yet reported Chong Kun Dang Pharmaceutical 64 participants Est. completion 2022-06-20 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05552495

    Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

    Not yet reported Chong Kun Dang Pharmaceutical 31 participants Est. completion 2022-12-12 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
  • Completed NCT NCT05698043

    A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

    Not yet reported Chong Kun Dang Pharmaceutical 63 participants Est. completion 2023-09-26 1 site Stand-alone
    Other conditions: Hypertension and Dyslipidemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.